Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

키워드

참고문헌 (128)

1. Charlson FJ, "Global epidemiology and burden of schizophrenia : findings from the global burden of disease study 2016", Schizophr Bull, 44, pp.1195~1203 (2018)
2. Millier A, "Humanistic burden in schizophrenia : a literature review", J Psychiatr Res, 54, pp.85~93 (2014)
3. Howes OD, "The dopamine hypothesis of schizophrenia : version III--the final common pathway", Schizophr Bull, 35, pp.549~562 (2009)
4. Miyamoto S, "Treatments for schizophrenia : a critical review of pharmacology and mechanisms of action of antipsychotic drugs", Mol Psychiatry, 10, pp.79~104 (2005)
5. Foussias G, "Antipsychotics and schizophrenia : from efficacy and effectiveness to clinical decision-making", Can J Psychiatry, 55, pp.117~125 (2010)
6. Dold M, "Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders", Cochrane Database Syst Rev, 1, pp.CD009831~ (2015)
7. Hirsch L, "Second-generation antipsychotics and metabolic side effects : a systematic review of population-based studies", Drug Saf, 40, pp.771~781 (2017)
8. Brown AS, "Prenatal infection and schizophrenia : a review of epidemiologic and translational studies", Am J Psychiatry, 167, pp.261~280 (2010)
9. Khandaker GM, "Inflammation and immunity in schizophrenia : implications for pathophysiology and treatment", Lancet Psychiatry, 2, pp.258~270 (2015)
10. Boksa P, "Effects of prenatal infection on brain development and behavior : a review of findings from animal models", Brain Behav Immun, 24, pp.881~897 (2010)
11. Meyer U, "Developmental neuroinflammation and schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.20~34 (2013)
12. Tenn CC, "Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition", Psychopharmacology(Berl), 180, pp.366~376 (2005)
13. Romero E, "Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics", Neuropsychopharmacology, 32, pp.1791~1804 (2007)
14. Romero E, "Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats : implications for the etiopathology of schizophrenia", Mol Psychiatry, 15, pp.372~383 (2010)
15. Shi L, "Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring", J Neurosci, 23, pp.297~302 (2003)
16. Zuckerman L, "Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring", J Psychiatr Res, 39, pp.311~323 (2005)
17. Bakos J, "Prenatal immune challenge affects growth, behavior, and brain dopamine in offspring", Ann N Y Acad Sci, 1018, pp.281~287 (2004)
18. Cui K, "Effects of prenatal immune activation on hippocampal neurogenesis in the rat", Schizophr Res, 113, pp.288~297 (2009)
19. Fatemi SH, "Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring : implications for genesis of neurodevelopmental disorders", Schizophr Res, 99, pp.56~70 (2008)
20. Ling Z, "Progressive dopamine neuron loss following supra-nigral lipopolysaccharide(LPS)infusion into rats exposed to LPS prenatally", Exp Neurol, 199, pp.499~512 (2006)
21. Wang S, "Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide", Brain Res, 1265, pp.196~204 (2009)
22. Brown AS, "Exposure to prenatal infection and risk of schizophrenia", Front Psychiatry, 2, pp.63~ (2011)
23. Jonakait GM, "The effects of maternal inflammation on neuronal development : possible mechanisms", Int J Dev Neurosci, 25, pp.415~425 (2007)
24. Patterson PH, "Immune involvement in schizophrenia and autism : etiology, pathology and animal models", Behav Brain Res, 204, pp.313~321 (2009)
25. Cai Z, "Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration", Pediatr Res, 47, pp.64~72 (2000)
26. Gayle DA, "Maternal LPS induces cytokines in the amniotic fluid and corticotropin releasing hormone in the fetal rat brain", Am J Physiol Regul Integr Comp Physiol, 286, pp.R1024~R1029 (2004)
27. Gilmore JH, "Maternal poly I : C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat", J Neuroimmunol, 159, pp.106~112 (2005)
28. Urakubo A, "Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain", Schizophr Res, 47, pp.27~36 (2001)
29. Samuelsson AM, "Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA", GABA(A)dysregulation and impaired spatial learning, 2006, pp.290, R1345~R1356
30. Smith SE, "Maternal immune activation alters fetal brain development through interleukin-6", J Neurosci, 27, pp.10695~10702 (2007)
31. Allswede DM, "Elevated maternal cytokine levels at birth and risk for psychosis in adult offspring", Schizophr Res, 172, pp.41~45 (2016)
32. Buka SL, "Maternal cytokine levels during pregnancy and adult psychosis", Brain Behav Immun, 15, pp.411~420 (2001)
33. Brown AS, "Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring", Am J Psychiatry, 161, pp.889~895 (2004)
34. Brown AS, "Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia", Biol Psychiatry, 49, pp.473~486 (2001)
35. Brown AS, "Association of maternal genital and reproductive infections with verbal memory and motor deficits in adult schizophrenia", Psychiatry Res, 188, pp.179~186 (2011)
36. Ellman LM, "Cognitive functioning prior to the onset of psychosis : the role of fetal exposure to serologically determined influenza infection", Biol Psychiatry, 65, pp.1040~1047 (2009)
37. Brown AS, "Prenatal infection and cavum septum pellucidum in adult schizophrenia", Schizophr Res, 108, pp.285~287 (2009)
38. Ellman LM, "Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8", Schizophr Res, 121, pp.46~54 (2010)
39. Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia : clinical status and antipsychotic effects", Biol Psychiatry, 70, pp.663~671 (2011)
40. Abdullah Bolu, "Serum Levels of High Sensitivity C-reactive Protein in Drug-naïve First-episode Psychosis and Acute Exacerbation of Schizophrenia", Clinical Psychopharmacology and Neuroscience, 17(2), pp.244~249 (2019), 대한정신약물학회[DOI]
41. Monji A, "Neuroinflammation in schizophrenia especially focused on the role of microglia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.115~121 (2013)
42. Furukawa H, "Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice", Ann N Y Acad Sci, 840, pp.117~122 (1998)
43. Müller N, "The role of inflammation in schizophrenia", Front Neurosci, 9, pp.372~ (2015)
44. Nair A, "Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation", J Neuroimmunol, 171, pp.72~85 (2006)
45. Sparkman NL, "Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress", Neuroimmunomodulation, 15, pp.323~330 (2008)
46. Frank MG, "Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses", Brain Behav Immun, 21, pp.47~59 (2007)
47. Zhou D, "Exposure to physical and psychological stressors elevates plasma interleukin 6 : relationship to the activation of hypothalamic-pituitary-adrenal axis", Endocrinology, 133, pp.2523~2530 (1993)
48. Howes OD, "Inflammation and the neural di athesis-stress hypothesis of schizophrenia : a reconceptualization", Transl Psychiatry, 7, pp.e1024~ (2017)
49. Zalcman S, "Interleukin-2 and-6 induce behavioral-activating effects in mice", Brain Res, 811, pp.111~121 (1998)
50. Zalcman S, "Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats", Brain Res, 847, pp.276~283 (1999)
51. Behrens MM, "Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia", J Neurosci, 28, pp.13957~13966 (2008)
52. Block ML, "Microglia and inflammation-mediated neurodegeneration : multiple triggers with a common mechanism", Prog Neurobiol, 76, pp.77~98 (2005)
53. Parrott JM, "Kynurenine 3-monooxygenase : an influential mediator of neuropathology", Front Psychiatry, 6, pp.116~ (2015)
54. Stone TW, "Endogenous kynurenines as targets for drug discovery and development", Nat Rev Drug Discov, 1, pp.609~620 (2002)
55. Iaccarino HF, "The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood : Implications for schizophrenia", Schizophr Res, 150, pp.392~397 (2013)
56. Larsson MK, "Repeated LPS injection induces distinct changes in the kynurenine pathway in mice", Neurochem Res, 41, pp.2243~2255 (2016)
57. Pérez-Neri I, "Possible mechanisms of neurodegeneration in schizophrenia", Neurochem Res, 31, pp.1279~1294 (2006)
58. Trépanier MO, "Postmortem evidence of cerebral inflammation in schizophrenia : a systematic review", Mol Psychiatry, 21, pp.1009~1026 (2016)
59. van Kesteren CF, "Immune involvement in the pathogenesis of schizophrenia : a meta-analysis on postmortem brain studies", Transl Psychiatry, 7, pp.e1075~ (2017)
60. Doorduin J, "Neuroinflammation in schizophrenia-related psychosis : a PET study", J Nucl Med, 50, pp.1801~1807 (2009)
61. PK11195 positron emission tomography study, "Biol Psychiatry", 2008, 820~822
62. PBR28 PET brain imaging study, "Am J Psychiatry", 2016, 44~52
63. Millan MJ, "Altering the course of schizophrenia : progress and perspectives", Nat Rev Drug Discov, 15, pp.485~515 (2016)
64. El-Sayed El-Sisi A, "Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia", Biomed Pharmacother, 82, pp.425~431 (2016)
65. Brenhouse HC, "Nonsteroidal anti-inflammatory treatment prevents delayed effects of early life stress in rats", Biol Psychiatry, 70, pp.434~440 (2011)
66. Klausberger T, "Complementary roles of cholecystokininand parvalbumin-expressing GABAergic neurons in hippocampal network oscillations", J Neurosci, 25, pp.9782~9793 (2005)
67. Lewis DA, "Cortical inhibitory neurons and schizophrenia", Nat Rev Neurosci, 6, pp.312~324 (2005)
68. Rotaru DC, "The role of glutamatergic inputs onto parvalbumin-positive interneurons : relevance for schizophrenia", Rev Neurosci, 23, pp.97~109 (2012)
69. Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
70. Corsello SM, "The Drug Repurposing Hub : a next-generation drug library and information resource", Nat Med, 23, pp.405~408 (2017)
71. Laan W, "Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders : results from a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 71, pp.520~527 (2010)
72. Attari A, "Aspirin inclusion in antipsychotic treatment on severity of symptoms in schizophrenia : a randimized clinical trial", Iran J Psychiatry Behav Sci, 11, pp.e5848~ (2017)
73. Müller N, "Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia", Am J Psychiatry, 159, pp.1029~1034 (2002)
74. Akhondzadeh S, "Celecoxib as adjunctive therapy in schizophrenia : a double-blind, randomized and placebo-controlled trial", Schizophr Res, 90, pp.179~185 (2007)
75. Rapaport MH, "Celecoxib augmentation of continuously ill patients with schizophrenia", Biol Psychiatry, 57, pp.1594~1596 (2005)
76. Müller N, "Celecoxib treatment in an early stage of schizophrenia : results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment", Schizophr Res, 121, pp.118~124 (2010)
77. Chen G, "Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats : a potential neuroprotective mechanism of N-acetylcysteine", Mediators Inflamm, 2008, pp.716458~ (2008)
78. Csontos C, "Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn", Burns, 38, pp.428~437 (2012)
79. Janáky R, "Glutathione modulates the N-methyl-D-aspartate receptor-activated calcium influx into cultured rat cerebellar granule cells", Neurosci Lett, 156, pp.153~157 (1993)
80. Keller WR, "A review of anti-inflammatory agents for symptoms of schizophrenia", J Psychopharmacol, 27, pp.337~342 (2013)
81. Farokhnia M, "N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia : a randomized, double-blind, placebo-controlled study", Clin Neuropharmacol, 36, pp.185~192 (2013)
82. Kerksick C, "The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress", J Int Soc Sports Nutr, 2, pp.38~44 (2005)
83. Do KQ, "Redox dysregulation, neurodevelopment, and schizophrenia", Curr Opin Neurobiol, 19, pp.220~230 (2009)
84. Hashimoto K, "Targeting of NMDA receptors in new treatments for schizophrenia", Expert Opin Ther Targets, 18, pp.1049~1063 (2014)
85. Berk M, "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial", Biol Psychiatry, 64, pp.361~368 (2008)
86. Wehring HJ, "Adjunctive minocycline in clozapine-treated patients with schizophrenia : analyzing the effects of minocycline on clozapine plasma levels", Psychiatr Q, 89, pp.73~80 (2017)
87. Xiang YQ, "Adjunctive minocycline for schizophrenia : a meta-analysis of randomized controlled trials", Eur Neuropsychopharmacol, 27, pp.8~18 (2017)
88. Asanuma Y, "Effects of C-reactive protein and homocysteine on cytokine production : modulation by pravastatin", Arch Drug Inf, 1, pp.14~22 (2008)
89. Chen SF, "Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury", Life Sci, 81, pp.288~298 (2007)
90. Rosendo AB, "Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals", Inflammation, 33, pp.244~250 (2010)
91. Zhang J, "Statins, autophagy and cancer metastasis", Int J Biochem Cell Biol, 45, pp.745~752 (2013)
92. Wang Q, "High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities : the association with the up-regulation of NMDA receptor binding in the rat brain", Exp Neurol, 216, pp.132~138 (2009)
93. Vevera J, "Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission", Psychiatry Res, 133, pp.197~203 (2005)
94. Vevera J, "The effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal model", Physiol Behav, 158, pp.112~120 (2016)
95. Wang Q, "High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex : possible involvement of endothelial nitric oxide synthase", Br J Pharmacol, 144, pp.933~939 (2005)
96. Wang Q, "Chronic treatment with simvastatin upregulates muscarinic M1", 4 receptor binding in the rat brain, 2008, pp.154, 1100~1106
97. Shen H, "Adjunctive therapy with statins in schizophrenia patients : a meta-analysis and implications", Psychiatry Res, 262, pp.84~93 (2018)
98. Bazan NG, "Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection", Curr Opin Clin Nutr Metab Care, 10, pp.136~141 (2007)
99. Singer P, "Anti-inflammatory properties of omega-3 fatty acids in critical illness : novel mechanisms and an integrative perspective", Intensive Care Med, 34, pp.1580~1592 (2008)
100. Chalon S, "Omega-3 fatty acids and monoamine neurotransmission", Prostaglandins Leukot Essent Fatty Acids, 75, pp.259~269 (2006)
101. Cho M, "Adjunctive use of anti-inflammatory drugs for schizophrenia : a meta-analytic investigation of randomized controlled trials", Aust N Z J Psychiatry, 53, pp.742~759 (2019)
102. Javitt DC, "Effect of the neuroprotective peptide davunetide(AL-108)on cognition and functional capacity in schizophrenia", Schizophr Res, 136, pp.25~31 (2012)
103. Gozes I, "NAP(davunetide)provides functional and structural neuroprotection", Curr Pharm Des, 17, pp.1040~1044 (2011)
104. Sirén AL, "Erythropoietin--a novel concept for neuroprotection", Eur Arch Psychiatry Clin Neurosci, 251, pp.179~184 (2001)
105. Ehrenreich H, "Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin", Mol Psychiatry, 12, pp.206~220 (2007)
106. Mellon SH, "Neurosteroid regulation of central nervous system development", Pharmacol Ther, 116, pp.107~124 (2007)
107. Koenig HL, "Progesterone synthesis and myelin formation by Schwann cells", Science, 268, pp.1500~1503 (1995)
108. Pandurangi AK, "Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia", Curr Top Behav Neurosci (2019)[DOI]
109. Fink G, "Estrogen control of central neurotransmission : effect on mood, mental state, and memory", Cell Mol Neurobiol, 16, pp.325~344 (1996)
110. Kulkarni J, "Estrogen in severe mental illness : a potential new treatment approach", Arch Gen Psychiatry, 65, pp.955~960 (2008)
111. Arevalo MA, "Selective oestrogen receptor modulators decrease the inflammatory response of glial cells", J Neuroendocrinol, 24, pp.183~190 (2012)
112. Peesa JP, "A perspective review on role of novel NSAID prodrugs in the management of acute inflammation", J Acute Dis, 5, pp.364~381 (2016)
113. Farrar MA, "The molecular cell biology of interferon-gamma and its receptor", Annu Rev Immunol, 11, pp.571~611 (1993)
114. Müller N, "Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders", Expert Rev Neurother, 6, pp.1017~1038 (2006)
115. Grüber L, "Adjunctive recombinant human interferon gamma-1b for treatment-resistant schizophrenia in 2 patients", J Clin Psychiatry, 75, pp.1266~1267 (2014)
116. Miller BJ, "An open-label, pilot trial of adjunctive tocilizumab in schizophrenia", J Clin Psychiatry, 77, pp.275~276 (2016)
117. Girgis RR, "A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia", Neuropsychopharmacology, 43, pp.1317~1323 (2018)
118. Weickert T, "Reduction in peripheral c-reactive protein levels with canakinumab administration is related to reduced positive symptom severity in patients with schizophrenia and inflammation", Schizophr Bull, 45, pp.S318~ (2019)
119. Siniscalco D, "Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?", J Biomed Biotechnol, 2012, pp.480289~ (2012)
120. Giuliani M, "Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation", PLoS One, 6, pp.e19988~ (2011)
121. Beggs KJ, "Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons", Cell Transplant, 15, pp.711~721 (2006)
122. Le Blanc K, "Mesenchymal stem cells : progress toward promise", Cytotherapy, 7, pp.36~45 (2005)
123. Guginski G, "Mechanisms involved in the antinociception caused by ethanolic extract obtained from the leaves of Melissa officinalis(lemon balm)in mice", Pharmacol Biochem Behav, 93, pp.10~16 (2009)
124. Siniscalco D, "Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice", Cell Mol Life Sci, 67, pp.655~669 (2010)
125. Uccelli A, "Mesenchymal stem cells in health and disease", Nat Rev Immunol, 8, pp.726~736 (2008)
126. Joyce N, "Mesenchymal stem cells for the treatment of neurodegenerative disease", Regen Med, 5, pp.933~946 (2010)
127. Lauren S. Sherman, "Mesenchymal stem cell therapies in brain disease", Seminars in Cell & Developmental Biology, 95, pp.111~119 (2019), Elsevier BV[DOI]
128. Ichim TE, "Stem cell therapy for autism", J Transl Med, 5, pp.30~ (2007)

관련 논문AI추천